Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7728032 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL3891070 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL10316599 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL25386399 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL8008366 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL25385320 | 0.97 | FFAR1 (0.36) | TDP1FFAR1CPT2 | |
| SCHEMBL231308 | 0.92 | — | — | |
| SCHEMBL27160388 | 0.85 | TDP1 (0.40) | TDP1FFAR1CPT2TSHR | |
| SCHEMBL1834842 | 0.82 | TDP1 (0.43) | TDP1FFAR1CPT2TSHR | |
| SCHEMBL1836223 | 0.82 | TDP1 (0.43) | TDP1FFAR1CPT2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333682-A | Organometallic compound, and organic light emitting device and diagnostic composition including the same | 三星电子株式会社 | 2020-06-26 | — | — | CN | claimed |
| US-6222025-B1 | OLIGONUCLEOTIDES HAVING 2' AND 5 SUBSTITUTED PYRIMIDINE NUCLEOTIDES; INCREASED AFFINITY FOR NUCLEIC ACIDS; INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | claimed |
| US-20240024252-A1 | LIPID NANOPARTICLE | NITTO DENKO CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2024018761-A1 | NEUTRAL LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| US-11781144-B2 | Inhibition of oxidative stress in atrial fibrillation | NORTHWESTERN UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023191050-A1 | PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION | 日東電工株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023188830-A1 | LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2023-10-05 | — | — | WO | disclosed |
| EP-4223314-A1 | LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116367718-A | Lipid nanoparticles | 国立大学法人北海道大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230122801-A1 | USP10 TARGETED SELF-DELIVERABLE SIRNA COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING FIBROSIS AND/OR SCARRING | UNIV NEW YORK STATE RES FOUND (US) | 2023-04-20 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018792-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5385693-A | Having rapid response and low phase transition temperature | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5264151-A | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024252-A1 | LIPID NANOPARTICLE | LIPC, ACOX1, ABCB4 | TDP1 4237/4885FFAR1 359/4885CPT2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.